Related references
Note: Only part of the references are listed.The diverse functions of the PD1 inhibitory pathway
Arlene H. Sharpe et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Leisha A. Emens et al.
EUROPEAN JOURNAL OF CANCER (2017)
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Recent advances of bispecific antibodies in solid tumors
Shengnan Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
James L. Gulley et al.
LANCET ONCOLOGY (2017)
Antibody Isotypes for Tumor Immunotherapy
Anna Kretschmer et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2017)
Atezolizumab for the treatment of non-small cell lung cancer
Fernando C. Santini et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential
Natalie J. Tigue et al.
ONCOIMMUNOLOGY (2017)
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study
Thomas Powles et al.
JAMA ONCOLOGY (2017)
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Anthony W. Tolcher et al.
CLINICAL CANCER RESEARCH (2017)
Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic
S. P. Kang et al.
ANNALS OF ONCOLOGY (2017)
The urgent need to recover MHC class I in cancers for effective immunotherapy
Federico Garrido et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Engineering antibody therapeutics
Mark L. Chiu et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2016)
Targeting regulatory T cells in tumors
Chang Liu et al.
FEBS JOURNAL (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Vaccines for established cancer: overcoming the challenges posed by immune evasion
Sjoerd H. van der Burg et al.
NATURE REVIEWS CANCER (2016)
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
B. Homet Moreno et al.
BRITISH JOURNAL OF CANCER (2015)
TNF Superfamily Protein-Protein Interactions: Feasibility of Small-Molecule Modulation
Yun Song et al.
CURRENT DRUG TARGETS (2015)
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
Bin Shang et al.
SCIENTIFIC REPORTS (2015)
Glucocorticoid-Induced Tumour Necrosis Factor Receptor-Related Protein: A Key Marker of Functional Regulatory T Cells
Simona Ronchetti et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2015)
Human Antibody Production in Transgenic Animals
Marianne Brueggemann et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2015)
Nivolumab: A Review of Its Use in Patients with Malignant Melanoma
Emma D. Deeks
DRUGS (2014)
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
Yannick Bulliard et al.
IMMUNOLOGY AND CELL BIOLOGY (2014)
Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer
Vanessa Gauttier et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
Xiaozhou Fan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Gene Expression in the Gitr Locus Is Regulated by NF-κB and Foxp3 through an Enhancer
Yukiko Tone et al.
JOURNAL OF IMMUNOLOGY (2014)
Antigen-specific vaccines for cancer treatment
Maria Tagliamonte et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
CD4 T Cells Require ICOS-Mediated PI3K Signaling to Increase T-Bet Expression in the Setting of Anti-CTLA-4 Therapy
Hong Chen et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
Jedd D. Wolchok et al.
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN USA 2012 (2013)
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Brendan D. Curti et al.
CANCER RESEARCH (2013)
Agonistic CD40 Antibodies and Cancer Therapy
Robert H. Vonderheide et al.
CLINICAL CANCER RESEARCH (2013)
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Agonistic Anti-CD40 Antibody Therapy is Effective Against Postoperative Cancer Recurrence and Metastasis in a Murine Tumor Model
Andrea Khong et al.
JOURNAL OF IMMUNOTHERAPY (2013)
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
Taku Okazaki et al.
NATURE IMMUNOLOGY (2013)
Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation
Henning Walczak
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability
David A. Schaer et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb
Aizea Morales-Kastresana et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2013)
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
Lomon So et al.
BIOCHEMICAL JOURNAL (2012)
Fc-fusion proteins: new developments and future perspectives
Daniel M. Czajkowsky et al.
EMBO MOLECULAR MEDICINE (2012)
Immunotherapy of Cancer with 4-1BB
Dass S. Vinay et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia
John C. Byrd et al.
LEUKEMIA & LYMPHOMA (2012)
被撤回的出版物: CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies (Retracted article. See vol. 134, pg. 658, 2019)
Holbrook E. Kohrt et al.
BLOOD (2011)
The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy
Tihui Fu et al.
CANCER RESEARCH (2011)
4-1BB signaling beyond T cells
Dass S. Vinay et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2011)
B7-H2 Is a Costimulatory Ligand for CD28 in Human
Sheng Yao et al.
IMMUNITY (2011)
CD8 T Cell-Intrinsic GITR Is Required for T Cell Clonal Expansion and Mouse Survival following Severe Influenza Infection
Laura M. Snell et al.
JOURNAL OF IMMUNOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
Adam D. Cohen et al.
PLOS ONE (2010)
Anti-CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy
Margaret K. Callahan et al.
SEMINARS IN ONCOLOGY (2010)
Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma
Sabine Middendorp et al.
BLOOD (2009)
CD28 and CTLA-4 coreceptor expression and signal transduction
Christopher E. Rudd et al.
IMMUNOLOGICAL REVIEWS (2009)
Fc-dependent expression of CD137 on human NK cells: insights into agonistic effects of anti-CD137 monoclonal antibodies
Wei Lin et al.
BLOOD (2008)
OX40 Drives Protective Vaccinia Virus-Specific CD8 T Cells
Shahram Salek-Ardakani et al.
JOURNAL OF IMMUNOLOGY (2008)
Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist
William L. Redmond et al.
JOURNAL OF IMMUNOLOGY (2007)
Role of endogenous 4-1BB in the development of systemic lupus erythematosus
Dass S. Vinay et al.
IMMUNOLOGY (2007)
Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb
Betty Li et al.
CLINICAL IMMUNOLOGY (2007)
Cutting edge:: OX40 inhibits TGF-β- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells
Takanori So et al.
JOURNAL OF IMMUNOLOGY (2007)
Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of oral alvespimycin (A; KOS-1022; 17-DMAG): Two different schedules in patients with advanced malignancies
K. T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
Robert H. Vonderheide et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Costimulation, coinhibition and cancer
Brant A. Inman et al.
CURRENT CANCER DRUG TARGETS (2007)
Tumor necrosis factor receptor (TNFR)-associated factor 5 is a critical intermediate of costimulatory signaling pathways triggered by glucocorticoid-induced TNFR in T cells
EM Esparza et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Costimulation of CD8 T cell responses by OX40
P Bansal-Pakala et al.
JOURNAL OF IMMUNOLOGY (2004)
GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations
S Ronchetti et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo
W Dawicki et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Synergistic B cell activation by CD40 and the B cell antigen receptor - Role of B lymphocyte antigen receptor-mediated kinase activation and tumor necrosis factor receptor-associated factor regulation
SA Haxhinasto et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
The CD40/CD40L costimulatory pathway in inflammatory bowel disease
S Danese et al.
GUT (2004)
Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity
CM Smith et al.
NATURE IMMUNOLOGY (2004)
CD40/CD154 interactions at the interface of tolerance and immunity
SA Quezada et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+ CD25+ T cells
GL Stephens et al.
JOURNAL OF IMMUNOLOGY (2004)
Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells
M Tone et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells
P Guermonprez et al.
NATURE (2003)
Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10
M Löhning et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody
AL Tutt et al.
JOURNAL OF IMMUNOLOGY (2002)
Stimulation of CD25+CD4+regulatory T cells through GITR breaks immunological self-tolerance
J Shimizu et al.
NATURE IMMUNOLOGY (2002)
CD4+CD25+ immunoregulatory T cells:: Gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor
RS McHugh et al.
IMMUNITY (2002)
CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-κB pathway
N Zhu et al.
JOURNAL OF IMMUNOLOGY (2002)
Phase I study of recombinant human CD40 ligand in cancer patients
RH Vonderheide et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells
MS Kuhns et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Engagement of the OX-40 receptor in vivo enhances antitumor immunity
AD Weinberg et al.
JOURNAL OF IMMUNOLOGY (2000)
Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand
K Murata et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
